Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Odyssey Therapeutics
company
About
Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.
- 101 - 250
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $168M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2021
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. The company's integrated drug-hunting engine is designed to accelerate drug discovery by unlocking targets with great potential and minimizing attrition.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$168M
Odyssey Therapeutics has raised a total of
$168M
in funding over 2 rounds. Their latest funding was raised on
Oct 13, 2022 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 13, 2022 | Series B | $168M | 1 |
General Catalyst
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Odyssey Therapeutics is funded by 1 investors.
General Catalyst
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
General Catalyst
|
Yes | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
